Shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Get Free Report) fell 8.2% during mid-day trading on Friday . The company traded as low as $2.89 and last traded at $2.93. 543,082 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 870,522 shares. The stock had previously closed at $3.19.
Can-Fite BioPharma Stock Down 8.2%
The stock has a market capitalization of $1.92 million, a price-to-earnings ratio of -1.64 and a beta of 1.09. The company’s fifty day simple moving average is $3.56 and its 200 day simple moving average is $5.15.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers raised its holdings in Can-Fite BioPharma by 42.4% in the 1st quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after acquiring an additional 11,388 shares during the period. Jane Street Group LLC bought a new position in Can-Fite BioPharma in the 4th quarter valued at about $41,000. Finally, Sabby Management LLC raised its holdings in Can-Fite BioPharma by 80.3% in the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after acquiring an additional 626,306 shares during the period. 21.00% of the stock is owned by institutional investors.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.
The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).
Further Reading
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
